We would love to hear your thoughts about our site and services, please take our survey here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSKIN.L Regulatory News (SKIN)

  • There is currently no data for SKIN

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Doubling of production of Modern Water reagent

6 May 2020 07:00

RNS Number : 0325M
Integumen PLC
06 May 2020
 

AIM share code: SKIN

6 May 2020

 

Integumen PLC

 

("Integumen" or "Company")

 

Integumen to double production of Modern Water reagent to meet demand

 

RAWTest AI real-time alert system to be retrofitted in new Modern Water's Microtox units

 

Further to the previous notification of production commencement (RNS[i] dated 30 March 2020), Integumen announces completion of the first batch of reagent for Modern Water plc ("MW"). Shipment has commenced to meet the back-orders and growing demand for water contamination detection bacteria from existing clients. With the increase of water hygiene controls around the world due to the COVID-19 public health crisis, Integumen has doubled production volume with a total list price value of £500,000 per batch, after the current initial production run. Revenues from sales of reagent produced under the revenue sharing manufacturing agency agreement with MW are split 60% / 40% in favour of Modern Water, after costs.

 

MW's Microtox is designed to be modular and expandable. Integumen is integrating its RAWTest[ii] AI real-time alert solution within MW's hardware capacity to expand the capability of the instruments to detect bacteria, nitrates and phosphates. The roadmap for this integration includes the ability to detect viruses such as SARS-Cov-2.

 

Integumen and MW have accelerated integration following increased orders of the Microtox range in Europe and SE Asia, including 10 new top-of-the-range Microtox CTM units to be shipped to China in the third quarter 2020.

 

The environmental arm of DEFRA[iii] has confirmed it is looking at wastewater epidemiology and US Center for Disease Control ("CDC") is already monitoring human waste[iv], the ministry of ecology[v] in China are mandating the hygiene monitoring of water and wastewater and dormant buildings during the epidemic have built up contaminated water in their pipework[vi]

 

Gerard Brandon CEO Integumen plc and Non-Executive Chairman of Modern Water commented:

"Due to the COVID19 outbreak, wastewater based epidemiology has recently become a high priority for governments looking to monitor for infection hotspots. The importance of SARS-CoV-2 or any future pandemic infections presented in wastewater to be identified quickly is critical to enable action to prevent the spread of infectious diseases within an enlarged community. This is evidenced by US CDC monitoring human waste[vii] the ministry of ecology in China mandating the hygiene monitoring of water and wastewater or simply that dormant buildings during the epidemic have built up contaminated water in their pipework[viii].

 

"With increasing demand, the unique combination of MW's gold standard water contamination detection system and Integumen's advanced real-time alert system are forming a vital part of society's frontline of defence against inevitable future outbreaks of infectious diseases."

 

Integumen plc

Gerard Brandon, CEO

+44 (0) 7340 055 648

SPARK Advisory Partners Limited

(Nominated Adviser)

Neil Baldwin/Andrew Emmott

+44 (0) 113 370 8974

Turner Pope Investments (TPI) Limited (Broker)

Andy Thacker/Zoe Alexander

+44 (0) 20 3657 0050

 

Market Abuse Regulation (MAR) Disclosure

 

Certain information contained in this announcement would have been deemed inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 until the release of this announcement.

 

About Integumen plc

Integumen is a scientific research and AI-as-a-Service company focused on production and analysis of bacteria, virus and toxins utilising artificial intelligent data analytics in regulatory technology, from scientifically proving the impact of skincare product claims on skin microbiome for top 10 global cosmetic company clients to remotely detecting water contamination in real-time.

 

About Modern Water plc

Modern Water was established in 2006 to develop and commercialise water recovery technologies to counter water crisis problems arising from climate change and a growing global population. Having invested £20m over the last 14 years, the results comprise of a robust patent portfolio of cutting edge technology, focused on monitoring of contaminated water and decontamination of wastewater, making recycling of water more efficient. Six countries across the world have legislated that Modern Water monitoring test systems are written into their environmental protection legislation.

 

About Microtox :

Microtox is a testing system which uses bioluminescent bacteria (Allivibrio fischeri) to detect toxic substances in different substrates such as water, air, soils and sediments. Allivibrio fischeri are non-pathogenic, marine, bacteria that glow (luminesce) as a natural part of their metabolism. When exposed to a toxic substance, the respiratory process of the bacteria is disrupted, reducing light output. Allivibrio fischeri have demonstrated high sensitivity across a wide variety of toxic substances. Response to toxicity is observed as a change in luminescence, which is a by-product of cellular respiration. This change can be used to calculate a percent inhibition of Allivibrio fischeri that directly correlates to the level of toxicity.


[i] https://www.londonstockexchange.com/exchange/news/market-news/market-news-detail/SKIN/14481945.html

[ii] http://watermon.rinodrive.com/

[iii] https://www.dailymail.co.uk/news/article-8288075/Government-considering-testing-SEWAGE-presence-coronavirus.html

[iv] https://www.politico.com/news/2020/05/01/cdc-human-waste-coronavirus-222253

[v] http://www.mee.gov.cn/xxgk2018/xxgk/xxgk15/202001/t20200131_761095.html

[vi] https://theconversation.com/the-coronavirus-pandemic-might-make-buildings-sick-too-136373

[vii] https://www.politico.com/news/2020/05/01/cdc-human-waste-coronavirus-222253

[viii] https://theconversation.com/the-coronavirus-pandemic-might-make-buildings-sick-too-136373

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
MSCAAMRTMTIMBTM
Date   Source Headline
28th Apr 20204:37 pmRNSPrice Monitoring Extension
28th Apr 20202:05 pmRNSSecond Price Monitoring Extn
28th Apr 20202:00 pmRNSPrice Monitoring Extension
17th Apr 20202:06 pmRNSSecond Price Monitoring Extn
17th Apr 20202:00 pmRNSPrice Monitoring Extension
30th Mar 20207:00 amRNSUpdate re COVID 19; confirmed orders; investment
23rd Mar 20207:00 amRNSDirector/PDMR Shareholding
18th Mar 202010:22 amRNSDirector/PDMR Shareholding
18th Mar 20207:00 amRNS3 year $3.75m (£3.12m) bacteria prod'n agreement
12th Mar 20202:06 pmRNSSecond Price Monitoring Extn
12th Mar 20202:00 pmRNSPrice Monitoring Extension
26th Feb 20207:00 amRNSLaunch of ecowaterOS; Company Update
7th Feb 20207:00 amRNSIntegumen plc to present at The UK Investor Show
3rd Feb 20207:00 amRNSCommercial & AI partnership with Acumen Software
21st Jan 20207:00 amRNSCooperative Alliance; Trading Update
19th Dec 20197:00 amRNS3-year Rev sharing Framework Ag with Parity Group
16th Dec 20198:43 amRNSDirector/PDMR Shareholdings
9th Dec 201911:05 amRNSPlacing/Subscription to raise £1.368m -replacement
9th Dec 20197:00 amRNSPlacing and subscription to raise £1.368 million
20th Nov 20197:00 amRNSResults of AI water research project
13th Nov 20197:00 amRNSHeads of Terms -Framework Agreement;trading update
7th Nov 20197:00 amRNSMicrobiome and Labskin clone R&D agreements signed
29th Oct 20197:00 amRNSLaunch of ind. Rinodrive AI open-source eco-system
21st Oct 20197:00 amRNSRinocloud subsidiary wins "One To Watch" IT award
8th Oct 201912:34 pmRNSIssue of Equity: Shares in Lieu of Invoice
7th Oct 20197:00 amRNSLabskin signs multi-year service agreement
7th Oct 20197:00 amRNSLabskinAI creates virtual AI psoriasis skin model
11th Sep 20197:00 amRNSInterim Results
5th Sep 20197:00 amRNSLabskin breakthrough clones 16 human skin swabs
2nd Aug 20197:00 amRNSHighlands Nat. Resources agreement with Cellulac
1st Aug 20191:41 pmRNSExercise of Warrants
1st Aug 201911:32 amRNSExercise of Warrants
31st Jul 20194:30 pmRNSResult of AGM
31st Jul 20197:00 amRNSAGM - Trading Update
29th Jul 20197:00 amRNSCollaboration; Expansion of wound care division
19th Jul 20197:00 amRNSLabskinAI:agreementswith global cosmetic companies
12th Jul 20197:00 amRNSChange to interests of a significant shareholder
11th Jul 201910:38 amRNSExercise of Warrants (update)
10th Jul 201912:55 pmRNSExercise of warrants
8th Jul 20197:00 amRNSAGM Notice and Trading Update
28th Jun 20193:03 pmRNSExercise of Warrants
27th Jun 20197:00 amRNSFinal Results
21st Jun 20197:00 amRNSExercise of Warrants
20th Jun 20197:01 amRNSExecutive team and Labskin AI digital hub updates
20th Jun 20197:00 amRNSExercise of Warrants
10th Jun 20197:00 amRNSExercise of Warrant Shares and Call Option Shares
28th May 20197:30 amRNSExercise of Warrants
28th May 20197:00 amRNSNew Labskin AI contracts; additional lab space
21st May 20197:00 amRNSTrading update and Board changes
10th May 201912:19 pmRNSLaunch of Labskin human skin clone tests

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.